# Indobufen versus aspirin in dual antiplatelet therapy: a retrospective study of effects on serum uric acid levels and gout attacks in patients post-coronary stenting

## TL;DR

This study found that indobufen combined with clopidogrel lowers uric acid levels and reduces gout attacks more effectively than aspirin plus clopidogrel in heart patients.

## Contribution

The study introduces indobufen as a potential alternative to aspirin in dual antiplatelet therapy for managing uric acid and gout in coronary stenting patients.

## Key findings

- Indobufen plus clopidogrel significantly reduced serum uric acid levels at all follow-up points.
- The indobufen group had a lower probability of gout recurrence compared to the aspirin group.
- Cardiovascular safety profiles were comparable between the two treatment groups.

## Abstract

This retrospective study compared the effects of indobufen versus aspirin, each combined with clopidogrel, on serum uric acid (SUA) levels and gout attacks in patients undergoing coronary stenting.

Among 213 enrolled patients, 156 were included after propensity score matching and assigned to either the indobufen plus clopidogrel group (n = 78) or the aspirin plus clopidogrel group (n = 78). SUA levels were measured at baseline and at the 1-month, 6-month, and 1-year follow-ups. Gout attacks and major cardiovascular events were recorded throughout the study.

Baseline characteristics were comparable. The indobufen group showed significant reductions in SUA levels at all follow-ups (all, P < 0.001), whereas levels in the aspirin group remained stable. Although the initial gout attack rates at baseline were similar between groups, the probability of recurrence during follow-up was lower in the indobufen group. Cardiovascular safety profiles were comparable between groups.

Indobufen plus clopidogrel significantly reduced SUA levels and showed a favorable trend in reducing gout recurrences without compromising cardiovascular safety.